CN109963597A - 聚乙二醇化血管内皮抑制素类似物及其应用 - Google Patents

聚乙二醇化血管内皮抑制素类似物及其应用 Download PDF

Info

Publication number
CN109963597A
CN109963597A CN201780069252.1A CN201780069252A CN109963597A CN 109963597 A CN109963597 A CN 109963597A CN 201780069252 A CN201780069252 A CN 201780069252A CN 109963597 A CN109963597 A CN 109963597A
Authority
CN
China
Prior art keywords
polyethylene glycol
vascellum esoderma
esoderma inhibin
analog
lysine residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780069252.1A
Other languages
English (en)
Other versions
CN109963597B (zh
Inventor
周代福
王文超
李辉
常国栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protgen Ltd
Original Assignee
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protgen Ltd filed Critical Protgen Ltd
Priority to CN202210948599.6A priority Critical patent/CN115721730A/zh
Publication of CN109963597A publication Critical patent/CN109963597A/zh
Application granted granted Critical
Publication of CN109963597B publication Critical patent/CN109963597B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明提了供聚乙二醇修饰的血管内皮抑制素类似物及其应用，所述血管内皮抑制素类似物在远离nucleolin结合区域的赖氨酸与聚乙二醇偶联或者在远离nucleolin结合区域的赖氨酸以及N端的氨基与聚乙二醇偶联。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201780069252.1A 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用 Active CN109963597B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210948599.6A CN115721730A (zh) 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610997233 2016-11-10
CN2016109972332 2016-11-10
PCT/CN2017/110532 WO2018086603A1 (zh) 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210948599.6A Division CN115721730A (zh) 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用

Publications (2)

Publication Number Publication Date
CN109963597A true CN109963597A (zh) 2019-07-02
CN109963597B CN109963597B (zh) 2022-08-26

Family

ID=62110381

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210948599.6A Pending CN115721730A (zh) 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用
CN201780069252.1A Active CN109963597B (zh) 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210948599.6A Pending CN115721730A (zh) 2016-11-10 2017-11-10 聚乙二醇化血管内皮抑制素类似物及其应用

Country Status (7)

Country Link
US (1) US11098104B2 (zh)
EP (1) EP3539570B1 (zh)
JP (1) JP7140454B2 (zh)
CN (2) CN115721730A (zh)
AU (1) AU2017357327B2 (zh)
CA (1) CA3043380A1 (zh)
WO (1) WO2018086603A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111166869A (zh) * 2019-12-30 2020-05-19 江苏大学 一种量子点与重组人内皮抑制素偶联物及其制备工艺
CN114438047A (zh) * 2020-11-05 2022-05-06 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210143127A (ko) * 2020-05-19 2021-11-26 애니젠 주식회사 신규 뉴클레오린-결합 펩타이드 및 이의 용도
CN115703828A (zh) * 2021-08-09 2023-02-17 刘鹏 一种抗血管生成药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082483A1 (fr) * 2006-01-20 2007-07-26 Tsinghua University Médicament pour le traitement de tumeurs et son utilisation
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
CN101596320A (zh) * 2006-01-20 2009-12-09 清华大学 一种***的药物及其应用
JP2013532126A (ja) * 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
JP6336389B2 (ja) * 2011-09-09 2018-06-06 チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Ａｔｐ結合部位に変異を有するエンドスタチン変異体
EP3246043A4 (en) 2014-11-03 2018-09-05 Tsinghua University Drug for inhibiting adipose cell differentiation and insulin resistance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007082483A1 (fr) * 2006-01-20 2007-07-26 Tsinghua University Médicament pour le traitement de tumeurs et son utilisation
CN101596320A (zh) * 2006-01-20 2009-12-09 清华大学 一种***的药物及其应用
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
JP2013532126A (ja) * 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111166869A (zh) * 2019-12-30 2020-05-19 江苏大学 一种量子点与重组人内皮抑制素偶联物及其制备工艺
CN114438047A (zh) * 2020-11-05 2022-05-06 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法

Also Published As

Publication number Publication date
AU2017357327A1 (en) 2019-06-13
EP3539570A4 (en) 2020-06-17
EP3539570A1 (en) 2019-09-18
JP7140454B2 (ja) 2022-09-21
JP2019535700A (ja) 2019-12-12
CN115721730A (zh) 2023-03-03
AU2017357327B2 (en) 2023-04-06
US20200270333A1 (en) 2020-08-27
WO2018086603A1 (zh) 2018-05-17
CN109963597B (zh) 2022-08-26
EP3539570B1 (en) 2022-04-13
US11098104B2 (en) 2021-08-24
CA3043380A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
CN100475270C (zh) 一种***的药物及其应用
JP7054407B2 (ja) オキシム連結のための求核触媒
US8901277B2 (en) Interferon alpha mutant and its polyethylene glycol derivative
CN109963597A (zh) 聚乙二醇化血管内皮抑制素类似物及其应用
JP7014844B2 (ja) オキシム連結のための求核触媒
CN101219219B (zh) 包含血管抑素或其片段的复合物、其制备方法及应用
Veronese et al. PEGylation: Posttranslational bioengineering of protein biotherapeutics
JP2011507913A (ja) Ｙ型ポリエチレングリコール修飾したｇ−ｃｓｆならびにその製造方法および使用
KR20150139982A (ko) 제약학적으로 용도되는 신규한 뉴트린 접합체
KR101483814B1 (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
CN101596320B (zh) 一种***的药物及其应用
CN103083681A (zh) 一种***的药物及其应用
EA047322B1 (ru) Способ получения модифицированного терапевтического белка (варианты)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant